San Francisco startup Framework Therapeutics is usually working on an oral, at the time-everyday GLP-1 drug called GSBR-1290—the drug surpassed Wall Street’s expectations in June any time a mid-stage study confirmed average weight loss of about 6% and it strategies to begin An additional mid-stage trial towards the top of the yr—that founder